Dubai: GlobalPharma, a wholly-owned subsidiary of Dubai Investments PJSC, hosted His Excellency Dr Amin Hussain Al Amiri, Assistant Undersecretary for Medical Practice and Licence Sector in the UAE Ministry of Health and his accompanying delegation, Dr Ruqaya Al Bastaki, Director of Drug Department, Ministry of Health and Prevention (MoHAP); and Dr Rita Al Shalouhi, Expert in Pharmaceutical Policies; to the facility located at Dubai Investment Park (DIP).

Abdulaziz Bin Yagub Al Serkal, CEO of Industrial Platform - Dubai Investments PJSC; along with Dr Bassem Albarameh, Acting General Manager of Globalpharma; Dr Idrees Siddiqui, Director of the Globalpharma Site; and Mohamed Alloush, Director of Regulatory Affairs and Registration; welcomed the officials to the Globalpharma facility.

The inspection tour, part of MoHAP’s strategy, aimed at implementing national standards, strengthening, monitoring, and supervising the role of medical and pharmaceutical institutions, and reinforcing the role of inspection by increasing the number of judicial inspectors across the country.

As part of the inspection visit, HE Dr Amin discussed the company's future plans for the advancement of the pharmaceutical industry in the country and ways and areas of cooperation with the Ministry of Health to promote and develop ambitious plans in line with UAE Vision 2030.

The flexibility of the MoHAP’s inspection teams dealing with the health facilities and local production facilities, as well as their continuous communication with them, helps increase the adherence to laws and enhance the spirit of responsibility and self-censorship among manufacturers and healthcare facilities.

MoHAP stressed on the importance of exports, encouraging local factories to enhance exporting to other countries so that the UAE drug is available across all countries of the region, enhancing the national economy.


About Globalpharma

Globalpharma is a leading pharmaceutical company in the UAE which was established in 1998 and started operations in 2003. It is a wholly owned subsidiary of Dubai Investments. The Globalpharma manufacturing facility in Dubai Investments Park covers an area of 27.000 square metres and the annual capacity of the plant includes the production of 300 million tablets, 150 million capsules, and over 7 million litres of dry syrup and liquid.

© Press Release 2020

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.